Abstract
Organ transplantation is currently the only effective treatment for end-stage organ failure. However, success is limited by the immune response of the recipient to allogeneic tissues (recognized by the direct and indirect alloresponses) and by the morbidity and mortality associated with the immunosuppressive drugs that are used to control alloimmunity. One solution to these problems is the induction of immunological tolerance. In our laboratory, we have selected two strategies to achieve this goal. The first is to expand and/or generate Tregs directly in vivo using infusions of 'tolerogenic' DCs into patients; the second is to purify Tregs from the blood of patients on the waiting list for a transplant, enrich and expand these cells in vitro and then inject back in vivo after transplantation. Here, we have summarized our results both in the murine and human systems on the use of Treg-based strategies to induce tolerance to the transplanted organs.
| Original language | English |
|---|---|
| Pages (from-to) | 28-31 |
| Number of pages | 4 |
| Journal | Immunotherapy |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2011 |
Keywords
- Animals
- Blood Transfusion, Autologous
- Cell Proliferation
- Cell- and Tissue-Based Therapy
- Clinical Trials as Topic
- Graft Rejection
- Humans
- Isoantigens
- Mice
- Organ Transplantation
- T-Lymphocytes, Regulatory
- Transplantation Tolerance
